论文部分内容阅读
头孢三嗪(Ceftriaxone,CTRX)是一种新的第三代头孢菌素,其抗菌谱广,抗菌活性强,对绝大多数革蓝氏阴性菌和革蓝氏阳性菌均有良好的抗菌活性~[1～10];对大多数β-内酰胺酶稳定~[1,5,9,11];特别值得注意的是在药代动力学方面具有突出的优点,在体内能维持长时间的有效血浓度,半寿期约8小时~[12,13,14]。本药易透入组织及脑脊液内~[14,15,16]。临床上已用于治疗各种感染,疗效良好~[16,17,18]。对敏感菌所致的脑膜炎疗效亦很显著~[17～20],毒副反应低~[10～20]。 国产头孢三嗪已由四川抗菌素工业研究所试制成功,本文报道它对430株致病菌的体外抗菌作用研究结果,并与瑞士 Roche公司制造的药品Rocephin进行比较。
Ceftriaxone (CTRX) is a new third-generation cephalosporin with broad antibacterial spectrum and strong antibacterial activity. It has good antibacterial activity against most of the gram-negative and gram-positive bacteria ~ [1-10]; stable to most [beta] -lactamases ~ [1, 5, 9, 11]; of particular note is its outstanding pharmacokinetic advantages over the long term in the body Effective blood concentration, half-life of about 8 hours ~ [12,13,14]. The drug easily penetrate into the tissues and cerebrospinal fluid ~ [14,15,16]. Clinically used to treat various infections, good effect ~ [16,17,18]. Meningitis caused by sensitive bacteria is also very effective ~ [17 ~ 20], low toxicity [10 ~ 20]. The domestic ceftriaxone has been successfully tested by the Sichuan Institute of Antibiotics. This paper reports its in vitro antibacterial activity against 430 pathogens and compares it with the Rocephin drug manufactured by Roche, Switzerland.